
price data provid thomson reuter
number may add due round
reiter outperform rate target share bottom line see
strong oper execut report evidenc top-/
bottom-lin beat rais guidanc step back acknowledg
biosimilar entrant repres meaning threat almost large-cap biotech
player know agent success complet registr
effort enabl near-term approv soliri biosimilar product us/eu
anticip still sever year prior potenti approval/launch
bottom line ultomiri offer dose advantag price benefit
mainten vs soliri see platform strong foot soliris/
demonstr strong execut print report
financi result includ total revenu beat consensu
ws despit headwind revenu reduct
also beat consensu ws
guidanc rais go along beat follow report
manag increas revenu ep guidanc total revenu
increas guidanc midpoint
combin soliris/ultomiri guidanc increas
revenu guidanc rang bracket pre-exist
consensu ep rang increas
ahead consensu
acknowledg biosimilar competit repres meaning threat
large-cap biotech univers think well posit
regard soliri first foremost knowledg agent
success complet registr studi gain entri us/
program advanc still sever year market addit
import note ultomiri offer dose advantag vs soliri biosimilar
well potenti price benefit pnh mainten although
dismiss threat success convert us pnh
market thu far think compani continu execut strategi
continu hold posit bia limit chang estim stay
consist valuat methodolog continu deriv target
share via multipl appli non-gaap ep estim
discount back per year reiter outperform rate share
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
alexion pharmaceut inc commercial-stag biopharmaceut compani focus develop
novel therapi rare diseas compani flagship product soliri eculizumab market
sinc approv treatment three differ therapeut indic includ paroxysm
nocturn hemoglobinuria pnh atyp hemolyt urem syndrom ahu gener myasthenia gravi
gmg beyond soliri market product portfolio encompass three addit drug recent
gain approv late call ultomiri ravulizumab-cwvz midst pipelin expans
current effort includ differ program span rang autoimmun rare diseas see
ultomiri launch enabl strong revenue/ep growth profil pipelin larg remain unmodel
stage risk/reward appear favor
major pre-exist soliri
patient convert ultomiri
pnh assum approv
ahu gmg follow
program delay fail
pipelin candid appli
progress prior biosimilar/
ultomiri sbla pdufa ahu indic
potenti approv iv ultomiri ahu
target deriv multipl
ep discount back premium vs large-
cap consensu ep due orphan
product portfolio pipelin
inc headquart
boston center excel locat new
ct flagship product soliri approv
three differ indic pnh ahu gmg
soliris/ultomiri compris major
revenu base repres primari valu driver
investor sentiment compani roll
ultomiri pnh note use limit sampl
creat bluematrix
wedbush view reiter outperform rate target share bottom line
see strong oper execut report evidenc top-/bottom-
line beat rais guidanc step back acknowledg biosimilar entrant
repres meaning threat almost large-cap biotech player know agent
success complet registr effort enabl near-term approv soliri
biosimilar product us/eu market addit although amgn abp recent start
phase studi anticip still sever year prior potenti approval/launch
bottom line ultomiri offer dose advantag price benefit mainten vs
soliri see platform strong foot soliris/ultomiri convers unfold
takeaway report total revenu beat consensu non-
gaap ep compani report also beat pre-exist consensu
despit one-tim revenu reduct overal complement franchis revenu
beat consensu coincid beat manag increas
revenu earn guidanc rang figur summar key result
quarter differ versu consensu wedbush secur research estim ws
guidanc updat follow report manag provid updat financi
guidanc result figur summar chang manag
total revenu guidanc impli growth prior
period midpoint rang assumpt remain somewhat consist although
note anticip fx headwind expect smaller previous anticip
vs previous off-set increment increas price
headwind vs previous
model updat follow updat make minor adjust
estim first moder non-gaap tax estim addit
adjust share count assumpt go forward base current trend
lower row soliris/ultomiri revenu estim off-set increas
estim geographi overal ww soliris/ultomiri revenu estim
move approxim ahead high-end
guidanc continu anticip success convers ultomiri adopt soliri
gmg nmosd patient see figur
remain impress commerci execut come month alexion
hear european patent offic epo part normal cours eu patent
issuanc process recal two patent focu composit matter formul
soliri would provid exclus grant appear
concern regard potenti biosimilar threat soliri manifest note
first foremost know biosimilar agent suffici complet
registr studi would enabl potenti approv near-term either eu
market us generium recent approv eculizumab biosimilar agent
repres one agent knowledg suffici gener data would
permit approv broader geographi also recent start phase studi adult
pnh see product abp current primari complet date list
juli assum on-tim readout subsequ file review see
earliest potenti approv absent exclus restrict would note
assum delay accrual patient subsequ file
second regard european regulatori exclus note hold exclus
ahu indic gmg indic thu would limit abil
biosimilar approv indic
lastli note ultomiri chang potenti treatment paradigm pnh thu
remain unclear competit potenti soliri biosimilar agent may versu ultomiri
manag indic us pnh market alreadi convert soliri
ultomiri note price mainten year repres discount
current soliri thu assum earliest potenti biosimilar entrant reach market
soon major soliri patient alreadi convert ultomiri
competitor need price even lower point competit ultomiri still
address differ dose frequenc soliri biosimilar use every-
other-week dose compar everi eight week ultomiri
bottom line acknowledg biosimilar threat bear monitor still see hold
strong competit posit addit pipelin effort progress help
broaden potenti portfolio see multipl potenti call option yet
assign formal credit estim backdrop stay consist
valuat methodolog appli multipl ep estim discount
back per year yield target share see figur multipl
in-lin large-cap peer group current trade consensu ep
estim given share current trade see favor risk/reward setup
incom statement ms
good sold
 expens revenu
sg expens revenu
target deriv multipl ep discount back premium vs large-cap
consensu ep due orphan product portfolio pipelin
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
juli
juli
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
